Cytokines and depression: The need for a new paradigm

Brain, Behavior, and Immunity

Volumn 17, Issue 1 SUPPL., 2003, Pages 119-124

  Capuron, Lucile ^a   Dantzer, Robert ^b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT FRANÇOIS MAGENDIE   (France)

Author keywords

Antidepressants; Cancer; Cytokine; Depression; Indoleamine 2,3 deoxygenase; Symptoms; Tryptophan

Indexed keywords

ALPHA INTERFERON; CYTOKINE; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 6; PAROXETINE; TRYPTOPHAN; TUMOR NECROSIS FACTOR ALPHA;

ANHEDONIA; APPETITE DISORDER; AUTONOMIC NEUROPATHY; BEHAVIOR; BRAIN FUNCTION; CARCINOMA; COGNITION; COGNITIVE DEFECT; CONFERENCE PAPER; CROSS ALLERGY; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; FATIGUE; HUMAN; HYPOTHALAMUS HYPOPHYSIS SYSTEM; IMMUNE SYSTEM; IMMUNOPATHOGENESIS; MOOD; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; SIDE EFFECT; SLEEP DISORDER; VIRUS INFECTION; IMMUNOLOGY; IMMUNOMODULATION; PHYSIOLOGY; REVIEW;

CYTOKINES; DEPRESSION; HUMANS; NEUROIMMUNOMODULATION;

EID: 0037293033     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-1591(02)00078-8     Document Type: Conference Paper

References (43)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders, fourth edition. American Psychiatric Association: Washington, DC.
2. Anisman H., Kokkinidis L., Borowski T., Merali Z. Differential effects of interleukin (IL)-1beta, IL-2 and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Res. 779:1998;177-187.
3. Anisman H., Ravindran A.V., Griffiths J., Merali Z. Endocrine and cytokine correlates of major depression and dysthymia with typical or atypical features. Mol. Psychiat. 4:1999;182-188.
4. Appels A., Bar F.W., Bar J., Bruggeman C., de Baets M. Inflammation, depressive symptomtology, and coronary artery disease. Psychosom. Med. 62:2000;601-605.
5. Capuron L., Ravaud A. Prediction of the depressive effects of interferon α therapy by the patient's initial affective state. N. Engl. J. Med. 340:1999;1370.
6. Capuron L., Ravaud A., Dantzer R. Early depressive symptoms in cancer patients receiving interleukin 2 and/or interferon α-2b therapy. J. Clin. Oncol. 18:2000;2143-2151.
7. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., Miller A.H. Neurobehavioral effects of interferon-α in cancer patients: Phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology. 26:2002;643-652.
8. Capuron L., Ravaud A., Neveu P., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiat. 7:2002;468-473.
9. Castanon N., Bluthe R.M., Dantzer R. Chronic treatment with the atypical antidepressant tianeptine attenuates sickness behavior induced by peripheral but not central lipopolysaccharide and interleukin-1β in the rat. Psychopharmacology. 154:2001;50-60.
10. Connor T.J., Harkin A., Kelly J.P., Leonard B.E. Olfactory bulbectomy provokes a suppression of interleukin-1β and tumour necrosis factor-α production in response to an in vivo challenge with lipopolysaccharide: Effect of chronic desipramine treatment. Neuroimmunomodulation. 7:2000;27-35.
11. Dantzer R., Wollman E., Vitkovic L., Yirmiya R. Cytokines and depression: Fortuitous or causative association? Mol. Psychiat. 4:1999;328-332.
12. Dantzer R., Wollman E., Yirmiya R. Cytokines, stress, and depression. 1999;Plenum Press/Kluwer Academic Publishers, New York.
13. Dantzer R. Cytokine-induced sickness behavior: Mechanisms and implications. Ann. NY Acad. Sci. 933:2001;222-234.
14. Delgado P.L., Price L.H., Miller H.L., Salomon R.M., Licinio J., Krystal J.H., Heninger G.R., Charney D.S. Rapid serotonin depletion as a provocative challenge test for patients with major depression: Relevance to antidepressant action and the neurobiology of depression. Psychopharmacol. Bull. 27:1991;321-330.
15. Dunn A.J., Swiergiel A.H. The reductions in sweetened milk intake induced by interleukin-1 and endotoxin are not prevented by chronic antidepressant treatment. Neuroimmunomodulation. 9:2001;163-169.
16. Haack M., Hinze-Selch D., Fenzel T., Kraus T., Kuhn M., Schuld A., Pollmacher T. Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: Effects of confounding factors and diagnosis. J. Psychiat. Res. 33:1999;407-418.
17. Hayley S., Brebner K., Lacosta S., Merali Z., Anisman H. Sensitization to the effects of tumor necrosis factor-α: Neuroendocrine, central monoamine, and behavioral variations. J. Neurosci. 19:1999;5654-5665.
18. Hayley S., Lacosta S., Merali Z., van Rooijen N., Anisman H. Central monoamine and plasma corticosterone changes induced by a bacterial endotoxin: Sensitization and cross-sensitization effects. Eur. J. Neurosci. 13:2001;1155-1165.
19. Holsboer F. The corticosteroid receptor hypothesis of depression. Neuropsychopharmacology. 23:2000;477-501.
20. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., Shimizu T. Effect of single intracerebroventricular injection of α-interferon on monoamine concentrations in the rat brain. Eur. Neuropsychopharmacol. 10:2000;129-132.
21. Kubera M., Basta-Kaim A., Holan V., Simbirtsev A., Roman A., Pigareva N., Prokopieva E., Sham J. Effect of mild chronic stress, as a model of depression, on the immunoreactivity of C57BL/6 mice. Int. J. Immunopharmacol. 20:1998;781-789.
22. Kurzrock R. The role of cytokines in cancer-related fatigue. Cancer. 92:2001;1684-1688.
23. Lestage J., Verrier D., Palin K., Dantzer R. The enzyme indoleamine 2,3 dioxygenase is induced in the mouse brain in response to peripheral administration of lipopolysaccharide and superantigen. Brain Behav. Immun. 16:2002;596-601.
24. Levine J., Barak Y., Chengappa K.N., Rapoport A., Rebey M., Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology. 40:1999;171-176.
25. Maes M. Evidence for an immune response in major depression: A review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiat. 19:1995;11-38.
26. Maes M., Bonaccorso S., Marino V., Puzella A., Pasquini M., Biondi M.et al. Treatment with interferon-α (IFN α) of hepatitis C patients induces lower serum dipeptidyl peptidase IV activity, which is related to IFN α-induced depressive and anxiety symptoms and immune activation. Mol. Psychiat. 6:2001;475-480.
27. Malik U.R., Makower D.F., Wadler S. Interferon-mediated fatigue. Cancer. 92:2001;1664-1668.
28. Miller A.H., Pariante C.M., Pierce B.D. Effects of cytokines on glucocorticoid receptor expression and function: Glucocorticoid resistance and relevance to depression. Dantzer R., Wollman E., Yirmiya R. Cytokines, stress, and depression. 1999;107-116 Plenum/Kluwer Academic Publishers, New York.
29. Miyaoka H., Otsubo T., Kamijima K., Ishii M., Onuki M., Mitamura K. Depression from interferon therapy in patients with hepatitis C. Am. J. Psychiat. 156:1999;1120.
30. Moore P., Landolt H.P., Seifritz E., Clark C., Bhatti T., Kelsoe J.et al. Clinical and physiological consequences of rapid tryptophan depletion. Neuropsychopharmacology. 23:2000;601-622.
31. Moreno F.A., Gelenberg A.J., Heninger G.R., Potter R.L., McKnight K.M., Allen J.et al. Tryptophan depletion and depressive vulnerability. Biol. Psychiat. 46:1999;498-505.
32. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S.et al. Paroxetine for the prevention of depression induced by high-dose interferon α N. Engl. J. Med. 344:2001;961-966.
33. Pariante C.M., Pearce B.D., Pisell T.L., Sanchez C.I., Po C., Su C.et al. The proinflammatory cytokine, interleukin-1alpha, reduces glucocorticoid receptor translocation and function. Endocrinology. 140:1999;4359-4366.
34. Pariante C.M., Miller A.H. Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol. Psychiat. 49:2001;391-404.
35. Plata-Salaman C.R. Cytokines and anorexia: A brief overview. Semin. Oncol. 25(Suppl. 1):1998;64-72.
36. Pollmacher T., Schuld A., Kraus T., Haack M., Hinze-Selch D., Mullington J. Experimental immunomodulation, sleep, and sleepiness in humans. Ann. N. Y. Acad. Sci. 917:2000;488-499.
37. Rothermundt M., Arolt V., Peters M., Gutbrodt H., Fenker J., Kersting A.et al. Inflammatory markers in major depression and melancholia. J. Affect. Disord. 63:2001;93-102.
38. Schmidt E.D., Schoffelmeer A.N., De Vries T.J., Wardeh G., Dogterom G., Bol J.G.et al. A single administration of interleukin-1 or amphetamine induces long-lasting increases in evoked noradrenaline release in the hypothalamus and sensitization of ACTH and corticosterone responses in rats. Eur. J. Neurosci. 13:2001;1923-1930.
39. Smith R.S. The macrophage theory of depression. Med. Hypoth. 35:1991;298-306.
40. Yirmiya R. Endotoxin produces a depressive-like episode in rats. Brain Res. 711:1996;163-174.
41. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M.et al. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology. 24:2001;531-544.
42. Zalcman S., Savina I., Wise R.A. Interleukin-6 increases sensitivity to the locomotor-stimulating effects of amphetamine in rats. Brain Res. 847:1999;276-283.
43. Zalcman S. Interleukin-2 potentiates novelty- and GBR 12909-induced exploratory activity. Brain Res. 899:2001;1-9.